CCG 203971

Discontinued Product

CCG 203971 (Cat. No. 5277) has been withdrawn from sale for commercial reasons.
Cat.No. 5277 - CCG 203971 | C23H21ClN2O3 | CAS No. 1443437-74-8
Description: Inhibits the MRTF/SRF gene transcription pathway; antifibrotic agent
Chemical Name: N-(4-Chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidinecarboxamide
Purity: ≥98% (HPLC)
Citations (3)

Biological Activity for CCG 203971

CCG 203971 is an antifibrotic agent; inhibits fibrosis by targeting the MRTF/SRF gene transcription pathway. Selectively inhibits proliferation of SSc-derived dermal fibroblasts but not that of normal fibroblasts. Inhibits expression of CTGF, α-SMA, and COL1A2 in SSc fibroblasts as well as in LPA and in TGFβ-stimulated fibroblasts. Prevents bleomycin-induced skin thickening and collagen deposition in vivo. Also suppresses PC-3 cell migration in scratch wound assays (IC50 = 4.2 μM).

Compound Libraries for CCG 203971

CCG 203971 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for CCG 203971

M. Wt 408.88
Formula C23H21ClN2O3
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 1443437-74-8
PubChem ID 71681561
Smiles O=C(N2CCCC(C(NC3=CC=C(Cl)C=C3)=O)C2)C1=CC=CC(C4=CC=CO4)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for CCG 203971

References are publications that support the biological activity of the product.

Michel et al (2014) Hope for disease-modifying treatment of systemic sclerosis/scleroderma. J.Pharmacol.Exp.Ther. 350 480 PMID: 25053235

Bell et al (2013) Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg.Med.Chem.Lett. 23 3826 PMID: 23707258

Haak et al (2014) Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J.Pharmacol.Exp.Ther. 349 480 PMID: 24706986

View Related Products by Target

Keywords: CCG 203971, CCG 203971 supplier, CCG203971, antifibrotic, agent, inhibits, fibrosis, inhibitors, MRTF/SRF, gene, transcription, pathway, myocarin-related, factor, Systemic, sclerosis, connective, tissue, PC-3, cell, migration, Other, Transcription, Factors, 5277, Tocris Bioscience

3 Citations for CCG 203971

Citations are publications that use Tocris products. Selected citations for CCG 203971 include:

Zhu et al (2017) Similar regulatory mechanisms of caveolins and cavins by myocardin family coactivators in arterial and bladder smooth muscle. PLoS One 12 e0176759 PMID: 28542204

Lionarons et al (2019) RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell 36 68 PMID: 31257073

Osmanagic-Myers et al (2018) Endothelial progerin expression causes cardiovascular pathology through an impaired mechanoresponse. J Clin Invest PMID: 30422822

Reviews for CCG 203971

There are currently no reviews for this product. Be the first to review CCG 203971 and earn rewards!

Have you used CCG 203971?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review